Actively Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
Led by MacroGenics · Updated on 2026-02-05
250
Participants Needed
12
Research Sites
238 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.
CONDITIONS
Official Title
A Study of MGC026 in Participants With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years or older able to provide informed consent
- Adequate performance and lab test results
- Availability of archival or fresh tumor tissue sample for testing
- Unresectable, locally advanced or metastatic solid tumors including specific cancer types listed
- Measurable disease by RECIST v1.1 or metastatic castration resistant prostate cancer without measurable disease
- Willingness to use effective birth control from consent through 7 months after treatment
- Not pregnant or breastfeeding
You will not qualify if you...
- Medical or psychiatric conditions that interfere with treatment or study procedures
- Another cancer treated within past 2 years except low-risk skin or prostate cancers
- Prior central nervous system metastasis unless treated, asymptomatic, and stable
- Recent surgery or cancer treatments within protocol-specified intervals
- Prior treatment with B7-H3 targeted agents or ADCs with topoisomerase payloads
- Prior stem cell or solid organ transplant
- Significant cardiovascular, lung, or gastrointestinal disorders
- Active infections requiring intravenous treatment within 1 week before study drug
- Known hepatitis B or C infection or positive tests
- Known HIV infection or AIDS history
- History of primary immunodeficiency
- Major trauma or surgery within 4 weeks before study drug
- Known allergy to recombinant proteins
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
The Angeles Clinic and Research Institute
Los Angeles, California, United States, 90025
Actively Recruiting
2
START Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
3
START-New York Long Island
Lake Success, New York, United States, 11042
Actively Recruiting
4
Providence Cancer Institute
Portland, Oregon, United States, 97213
Actively Recruiting
5
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
6
University of Texas Health Science Center at Houston
Houston, Texas, United States, 77030
Actively Recruiting
7
START Mountain Region
West Valley City, Utah, United States, 84119
Actively Recruiting
8
ICON Cancer Centre Wesley
Auchenflower, Queensland, Australia, 4066
Actively Recruiting
9
ICON Cancer Centre Kurralta Park
Kurralta Park, South Australia, Australia, 5037
Actively Recruiting
10
Austin Health- Olivia Newton John Cancer Center
Heidelberg, Victoria, Australia, 3084
Actively Recruiting
11
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom, OX3 9DU
Actively Recruiting
12
The Royal Marsden NHS Foundation Trust
Sutton, United Kingdom, SM2 5PT
Actively Recruiting
Research Team
G
Global Trial Manager
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
12
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here